Realcan(SZ:002589) Xin Lang Zheng Quan·2025-12-02 01:23Group 1 - The core viewpoint of the news is that Ruikang Pharmaceutical's stock performance and financing activities indicate a mixed outlook, with a slight increase in stock price but a net financing outflow on December 1 [1] - On December 1, Ruikang Pharmaceutical's stock rose by 1.28%, with a trading volume of 226 million yuan. The financing buy-in amount was 21.75 million yuan, while the financing repayment was 30.12 million yuan, resulting in a net financing outflow of 8.37 million yuan [1] - As of December 1, the total balance of margin trading for Ruikang Pharmaceutical was 220 million yuan, with a financing balance of 219 million yuan, accounting for 4.61% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of October 31, the number of shareholders for Ruikang Pharmaceutical was 72,300, a decrease of 0.82% from the previous period, while the average circulating shares per person increased by 0.83% to 18,879 shares [2] - For the period from January to September 2025, Ruikang Pharmaceutical reported operating revenue of 5.407 billion yuan, a year-on-year decrease of 10.73%, and a net profit attributable to shareholders of 12.1366 million yuan, down 68.73% year-on-year [2] Group 3 - Ruikang Pharmaceutical has distributed a total of 393 million yuan in dividends since its A-share listing, with cumulative distributions of 36.0313 million yuan over the past three years [3]